July 2 (Reuters) - Arrowhead Research Corp ARWR.O :
* Says Arrowhead initiates dosing of ARC-AAT in patients with Alpha-1
Antitrypsin deficiency
* Says expects to complete enrollment of the phase 1 study by the end of 2015
* Says intends to open additional sites for enrollment in Europe, pending
regulatory permission to proceed
* Source text for Eikon ID:nBw4t6FXra
* Further company coverage ARWR.O